Australia's largest stock trading and investment forum Australia's #1 stock forum

SNT

8.33%

3.9¢ syntara limited

SNT - Research & Valuation, page-2

First 2 Last

Share
Profile

Follow
ma420

7,149 Posts.

1832

10/07/24

22:49

Post #: 74698887
Share

Originally posted by ma420: ↑

Constellation pharma had a Bromodomain and Extra-Terminal (BET) protein inhibitor called Pelabresib for MF and MDS.

Morphosys acquired Constellation for $1.7Bn in June 2021.
https://www.morphosys.com/en/news/morphosys-acquire-constellation-pharmaceuticals

Next Novartis acquired Morphosys in Feb 2024 for US $2.92 Bn (EUR $2.7 Bn)

https://www.novartis.com/news/media-releases/novartis-strengthen-oncology-pipeline-agreement-acquire-morphosys-ag-eur-68-share-or-aggregate-eur-27bn-cash

The focus of these acquisitions is the combined MF and MDS trial being trialled in combination with JAK inhibitor (Ruxolitinib)- https://clinicaltrials.gov/study/NCT02158858
No.of patients: 336

In the 1/7/24 preso slide 11, Gary has this transaction as successful phase 3- details of the trials here- https://clinicaltrials.gov/study/NCT04603495

Syntara SNT-5505 in MF: https://clinicaltrials.gov/study/NCT04676529
We are also doing a combination trial with the JAK inhibitor ruxolitinib
No.of patients: 39

From the looks of it, Constellation’s and Syntara’s MF trials have similar endpoints (at a high level) although vastly different patient populations.
So yes, at the December readout we may be in the crosshairs of some BPs.

AIMO. DYOR.

Expand

Btw, Platinum asset mgmt were invested in Morphosys prior to the Novartis acquisition. They are likely seeing parallels here and hence invested in Syntara (20%).

SNT Price at posting: 3.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

There are more pages in this discussion • 23 more messages in this thread...

First 2 Last

Add SNT (ASX) to my watchlist

(20min delay)
Last 3.9¢		Change 0.003(8.33%)		Mkt cap ! $53.54M

Open	High	Low	Value	Volume
3.7¢	4.0¢	3.7¢	$80.41K	2.085M

Buyers (Bids)

No.	Vol.	Price($)
2	152202	3.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	25989	3

View Market Depth

No.	Vol.	Price($)
2	152202	0.039
2	831600	0.038
2	680000	0.037
4	503284	0.036
7	1339204	0.035

Price($)	Vol.	No.
0.040	15726	1
0.042	300000	1
0.043	200000	1
0.044	358500	1
0.045	1900	1

Last trade - 16.10pm 27/09/2024 (20 minute delay)

SNT (ASX) Chart

SNT - Research & Valuation, page-2

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

SNT - Research & Valuation, page-2

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News